W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Miasta: Gdańsk, Gliwice, Kraków, Poznań i 2 inne miastaWiek: od 0 latSponsor: Sanofi-Aventis Recherche & Developpement
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza I
A Phase 1 first-in-human study to evaluate SAR447754 in healthy adult participants and in adult participants with moderate-to-severe atopic dermatitis.
Miasta: Gdańsk, WrocławWiek: 18-64 latSponsor: Sanofi-Aventis Recherche & Developpement
RekrutujeFaza III
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
Miasta: Poznań, Warszawa, WrocławWiek: do 17.99 latSponsor: Sanofi-Aventis Recherche & Developpement
RekrutujeFaza II/III
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD)…
Miasta: Białystok, Chęciny, Kraków, Ostrowiec Świętokrzyski i 2 inne miastaWiek: od 18 latSponsor: Sanofi-Aventis Recherche & Developpement
RekrutujeFaza II/III
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD)…
Miasta: Białystok, Elbląg, Katowice, Piaseczno i 2 inne miastaWiek: od 18 latSponsor: Sanofi-Aventis Recherche & Developpement
RekrutujeFaza III
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
Miasta: Gdańsk, Kraków, WrocławWiek: od 18 latSponsor: Sanofi-Aventis Recherche & Developpement
RekrutujeFaza III
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
Miasta: Bydgoszcz, Elbląg, Gdańsk, Katowice i 19 innych miastWiek: od 0 latSponsor: Sanofi-Aventis Recherche & Developpement
RekrutujeFaza III
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Miasta: Bydgoszcz, Częstochowa, Elbląg, Katowice i 20 innych miastWiek: od 0 latSponsor: Sanofi-Aventis Recherche & Developpement
RekrutujeFaza III
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Miasta: Bydgoszcz, Elbląg, Jelenia Góra, Katowice i 19 innych miastWiek: od 0 latSponsor: Sanofi-Aventis Recherche & Developpement
RekrutujeFaza III
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
Miasta: Bydgoszcz, Elbląg, Jelenia Góra, Katowice i 20 innych miastWiek: od 0 latSponsor: Sanofi-Aventis Recherche & Developpement
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza II
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
Miasta: Warszawa, Wrocław, ŁódźWiek: od 18 latSponsor: Sanofi-Aventis Recherche & Developpement
RekrutujeFaza II
A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission
Miasta: Bydgoszcz, WarszawaWiek: od 18 latSponsor: Sanofi-Aventis Recherche & Developpement
RekrutujeFaza IV
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
Miasta: Białystok, Ostrowiec Świętokrzyski, PoznańWiek: od 18 latSponsor: Sanofi-Aventis Recherche & Developpement
RekrutujeFaza III
A phase 3, multicenter, randomized, double-blind, placebo- controlled, parallel-group study with an open-label period and long-term extension to assess the efficacy and safety of…
Miasta: Bydgoszcz, Radom, ŁódźWiek: od 18 latSponsor: Sanofi-Aventis Recherche & Developpement
RekrutujeFaza III
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
Miasta: Gdańsk, Skórzewo, Słupsk, ŁódźWiek: od 18 latSponsor: Sanofi-Aventis Recherche & Developpement
RekrutujeFaza II
A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
Miasta: Chojnice, Kraków, Lublin, Piotrków Trybunalski i 3 inne miastaWiek: od 18 latSponsor: Sanofi-Aventis Recherche & Developpement
RekrutujeFaza III
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Miasta: Białystok, Lublin, Nadarzyn, Opole i 2 inne miastaWiek: do 64 latSponsor: Sanofi-Aventis Recherche & Developpement
RekrutujeFaza III
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
Miasta: Kraków, Lublin, RzeszówWiek: od 18 latSponsor: Sanofi-Aventis Recherche & Developpement
RekrutujeFaza II
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
Miasta: Chęciny, Katowice, Ostrowiec Świętokrzyski, Poznań i 1 inne miastoWiek: od 18 latSponsor: Sanofi-Aventis Recherche & Developpement
RekrutujeFaza II
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or…
Miasta: Opole, Poznań, ŁódźWiek: od 18 latSponsor: Sanofi-Aventis Recherche & Developpement
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating…
Miasta: Kraków, LublinWiek: od 18 latSponsor: Sanofi-Aventis Recherche & Developpement
W Polsce: ZakończoneNa świecie: RekrutujeFaza III
A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
Miasta: Szczecin, ZabrzeWiek: od 18 latSponsor: Sanofi-Aventis Recherche & Developpement
RekrutujeFaza III
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
Miasta: Kraków, Warszawa, WrocławWiek: od 18 latSponsor: Sanofi-Aventis Recherche & Developpement
Rekrutacja wkrótceFaza III
A Study to Investigate Long-term Safety and Tolerability of Frexalimab in Participants With Multiple Sclerosis
Miasta: Białystok, Bydgoszcz, Katowice, Kielce i 7 innych miastWiek: 18-64 latSponsor: Sanofi-Aventis Recherche & Developpement
Rekrutacja wkrótceFaza II
A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis
Miasta: Białystok, Wrocław, ŁódźWiek: od 18 latSponsor: Sanofi-Aventis Recherche & Developpement